Bulletin
Investor Alert

Denali Therapeutics Inc.

NAS: DNLI

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 24, 2022, 6:08 p.m.

/zigman2/quotes/200043077/composite

$

34.33

Change

-0.43 -1.24%

Volume

Volume 40,184

Quotes are delayed by 20 min

/zigman2/quotes/200043077/composite

Previous close

$ 32.36

$ 34.76

Change

+2.40 +7.42%

Day low

Day high

$31.11

$35.06

Open

52 week low

52 week high

$30.25

$83.98

Open

Marc Tessier-Lavigne

Founder of Denali Therapeutics, Inc. and Renovis, Inc., Marc Tessier-Lavigne is President of Stanford University, Member of National Academy of Sciences, Member of Institute of Medicine, Member of American Philosophical Society, Member of Royal Society of Canada, Member of National Academy of Medicine of United States and Member of The Royal Society and on the board of 6 other companies.

In his past career he held the position of Chairman for Agios Pharmaceuticals, Inc., Chief Scientific Officer & Executive VP-Research at Genentech, Inc., President, Trustee & Professor at The Rockefeller University, Professor at The University of California, San Francisco and Professor at Stanford University.

Marc Tessier-Lavigne received an undergraduate degree from McGill University, an undergraduate degree from the University of Oxford and a doctorate from University College London.

Transactions

Date Shares Transaction Value
12/30/2021 3,377   Disposition at $45.59 per share. 153,958
12/30/2021 3,343   Disposition at $45.13 per share. 150,870
12/30/2021 800   Disposition at $45.72 per share. 36,576
12/30/2021 6,002   Disposition at $45.31 per share. 271,951
12/30/2021 900   Disposition at $45.71 per share. 41,139
12/30/2021 5,625   Disposition at $45.31 per share. 254,869
12/29/2021 10,700   Disposition at $43.87 per share. 469,409
12/29/2021 10,700   Disposition at $43.88 per share. 469,516
12/29/2021 10,704   Disposition at $43.88 per share. 469,692
12/28/2021 3,602   Disposition at $44.38 per share. 159,857
12/28/2021 3,732   Disposition at $44.37 per share. 165,589
12/28/2021 3,646   Disposition at $44.37 per share. 161,774
10/04/2021 100,000   Gift at $0 per share. 0
10/04/2021 100,000   Gift at $0 per share. 0
10/04/2021 100,000   Gift at $0 per share. 0
10/04/2021 300,000   Gift at $0 per share. 0
06/07/2021 700   Disposition at $71.06 per share. 49,742
06/07/2021 93,678   Disposition at $70.34 per share. 6,589,311
06/07/2021 27,245   Derivative/Non-derivative trans. at $19.5 per share. 531,277
06/07/2021 27,830   Derivative/Non-derivative trans. at $18.92 per share. 526,543
06/07/2021 39,303   Derivative/Non-derivative trans. at $18 per share. 707,454
06/02/2021 2,074   Award at $0 per share. 0
05/24/2021 8,806   Disposition at $60.02 per share. 528,537
05/21/2021 37,957   Disposition at $60.13 per share. 2,282,355
05/03/2021 98   Disposition at $61.2 per share. 5,998
05/03/2021 3,139   Disposition at $60.08 per share. 188,592
04/01/2021 6,184   Disposition at $57.6 per share. 356,199
04/01/2021 29,593   Disposition at $56.91 per share. 1,684,138
04/01/2021 14,223   Disposition at $55.61 per share. 790,942
03/01/2021 1,031   Disposition at $71.35 per share. 73,562
03/01/2021 3,482   Disposition at $69.59 per share. 242,313
03/01/2021 6,011   Disposition at $68.5 per share. 411,754
03/01/2021 14,945   Disposition at $67.57 per share. 1,009,834
03/01/2021 18,316   Disposition at $66.55 per share. 1,218,930
03/01/2021 37,445   Disposition at $65.63 per share. 2,457,516
03/01/2021 18,770   Disposition at $64.36 per share. 1,208,038
06/16/2020 400,000   Disposition at $26.1 per share. 10,440,000
12/12/2017 25,000   Derivative/Non-derivative trans. at $0 per share. 0

Officers and Executives

Dr. Ryan J. Watts
President, Chief Executive Officer & Director
Dr. Alexander O. Schuth
Chief Operating Officer & Secretary
Mr. Steve E. Krognes
Treasurer, Chief Financial & Accounting Officer
Dr. Joe Lewcock
Chief Scientific Officer
Dr. Carole Ho
Chief Medical Officer & Head-Development
Dr. Dana Andersen
CTO & Chief Manufacturing Officer
Ms. Katie Peng
Chief Commercial Officer
Dr. Laura G. Hansen
Vice President-Investor Relations
Ms. Cindy Dunkle
Chief People Officer
Dr. Chris Walsh
Associate General Counsel
Ms. Erica Kratz
Vice President-Regulatory
Dr. Vicki L. Sato
Non-Executive Chairman
Ms. Nancy A. Thornberry
Independent Director
Dr. Marc Tessier-Lavigne
Independent Director
Dr. Douglas G. Cole
Independent Director
Mr. Jay T. Flatley
Independent Director
Mr. Robert Taylor Nelsen
Independent Director
Dr. David Paul Schenkein
Independent Director
Mr. Peter S. Klein
Independent Director
Ms. Jennifer E. Cook
Independent Director
Trending Tickers
  • /zigman2/quotes/207505872/composite DISH+1.05%
  • /zigman2/quotes/204151124/composite CURE-1.23%
  • /zigman2/quotes/214908404/composite GFL+1.15%
  • /zigman2/quotes/204236046/composite DUST+1.32%
  • /zigman2/quotes/200683073/composite FRC+0.90%
X
Powered by StockTwits
Link to MarketWatch's Slice.